Arsenous acid for hard-to-treat triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a medicine called arsenous acid for people with triple-negative breast cancer that has not responded to at least two prior treatments. If you join, you will get arsenous acid plus one of four chemotherapy drugs to see if the combination can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer (hormone receptor and HER2 negative) that has spread to other parts of the body.
- You have already tried at least 2 standard treatments for metastatic disease and they didn't work.
- You are in fairly good overall health (able to take care of yourself) and have adequate blood counts and organ function.
- You have at least one tumor that can be measured on a CT or MRI scan, or you have only bone metastases or stable brain metastases.
- You are willing to use contraception if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (camrelizumab and pirfenidone) with chemotherapy to see if it can help people with advanced triple-negative breast cancer. It may offer a new treatment option for those whose cancer has progressed after initial treatment.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.